InvestSMART

Alterity Therapeutics Limited (ASX: ATH) - Share Price

Current share price for ATH : $0.565 0.005 (0.89%)+

Alterity Therapeutics Limited (ATH, formerly Prana Biotechnology Limited), an ASX-listed company, is a clinical stage biotechnology company focused on neurodegenerative diseases. The company focusses to commercialise research into Parkinsonian movement disorders, Alzheimer disease, Huntington disease and other neurodegenerative disorders.

ATH General Information +

ASX Code ATH
Website N/A
Industry/Sector Biotechnology
Market Cap ($M) 122
ATH Share Price $0.565
Day High $0.575
Day Low $0.560
Last Close $0.560
ATH Share Price Movement $0.00 ( 0.89% )
Prices as at 15:05, 29 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Alterity Therapeutics Limited (ATH) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Alterity Therapeutics Limited (ATH) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Alterity Therapeutics Limited (ATH) price-sensitive announcements

ATH - Alterity and FDA Agree on Phase 3 Program for ATH434 in MSA
Alterity Therapeutics Limited announced that they have achieved alignment with the U.S. FD
Alterity Therapeutics Limited (ATH)
9 Jun 2026 | 9:01 AM
ATH - Quarterly Activities/Appendix 4C Cash Flow Report
Alterity Therapeutics Limited is progressing its ATH434 program for treating Multiple Syst
Alterity Therapeutics Limited (ATH)
30 Apr 2026 | 9:53 AM
ATH - Notice of General Meeting/Proxy Form
The document is a Notice of General Meeting for Alterity Therapeutics Limited, scheduled t
Alterity Therapeutics Limited (ATH)
29 Apr 2026 | 12:54 PM
ATH - Alterity Receives Positive FDA Feedback on CMC Meeting
Alterity Therapeutics Limited has announced receiving positive feedback from the FDA follo
Alterity Therapeutics Limited (ATH)
27 Apr 2026 | 8:56 AM

Alterity Therapeutics Limited (ATH) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Alterity Therapeutics Limited (ATH)
ORDINARY FULLY PAID
Health Care $123 Change of Director's Interest Notice x 2 17 Jun 2026 11:54AM $0.580 $0.565 fallen by 2.59%
Alterity Therapeutics Limited (ATH)
ORDINARY FULLY PAID
Health Care $123 Corporate Presentation June 2026 16 Jun 2026 10:40AM $0.510 $0.565 risen by 10.78%
Alterity Therapeutics Limited (ATH)
ORDINARY FULLY PAID
Health Care $123 Notification regarding unquoted securities - ATH 15 Jun 2026 2:41PM $0.480 $0.565 risen by 17.71%
Alterity Therapeutics Limited (ATH)
ORDINARY FULLY PAID
Health Care $123 Notification of cessation of securities - ATH 15 Jun 2026 2:32PM $0.480 $0.565 risen by 17.71%
Alterity Therapeutics Limited (ATH)
ORDINARY FULLY PAID
Health Care $123 Completion of Consolidation 12 Jun 2026 2:52PM $0.495 $0.565 risen by 14.14%
Alterity Therapeutics Limited (ATH)
ORDINARY FULLY PAID
Health Care $123 Alterity and FDA Agree on Phase 3 Program for ATH434 in MSA 9 Jun 2026 9:01AM $0.009 $0.565 risen by 6,177.78%

ATH Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2027F C2 -$7.00 35.30% 0.00 0.00 0.00% 0.0%
2026F C2 -$5.20 -53.70% 0.00 0.00 0.00% 0.0%
2025A -$14.35 -$11.20 -56.90% 0.00 0.00 0.00% 0.0%

ATH Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2025 A 2026 F 2027 F 2025 A 2026 F 2027 F 2025 A 2026 F 2027 F
Alterity Therapeutics Limited (ATH) $124M -0.5685 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
CSL Limited (CSL) $56,344M 0.1108 -0.1296 0.0166 12.6157 14.4937 14.2573 3.79% 3.06% 3.19%
Clinuvel Pharmaceuticals Limited (CUV) $507M 0.0287 -0.0028 0.1257 13.9972 14.0363 12.4690 0.50% 0.70% 1.53%
Mesoblast Limited (MSB) $2,693M 0.0301 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,321M -1.3893 0.0000 -0.1304 0.0000 291.9926 335.7602 0.00% 0.00% 0.00%

ATH Directors

Name Position Start Date
Dr David Stamler Chief Executive Officer, Managing Director 21 Nov 2025
Mr Julian Barbaczy Non-Executive Chairman, Non-Executive Director 21 Nov 2025
Mr Peter Ashley Marks Non-Executive Director 29 Jul 2005
Mr Lawrence Bernard Gozlan Non-Executive Director 8 Aug 2011
Ms Ann Cunningham Non-Executive Director 17 Apr 2026

Alterity Therapeutics Limited (ATH) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
7 Apr 2025 GOZLAN, Lawrence Buy Indirect Shares 4,545,455 $0.011 $50,000.000
7 Apr 2025 MELTZER, Brian Buy Direct Shares 2,272,727 $0.011 $25,000.000
7 Apr 2025 MARKS, Peter Buy Indirect Shares 1,818,182 $0.011 $20,000.000

See all changes in directors' interest & trades for Alterity Therapeutics Limited (ATH) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

ATH Management

Name Position
Abby Macnish Niven Company Secretary

ATH Calendar of Events

Date Event
25 February 2027 Report (Interim)
28 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.